What is the recommended management of peptic ulcer disease, including H. pylori testing and eradication, NSAID‑related ulcer treatment, and follow‑up?

Management of Peptic Ulcer Disease

All patients with peptic ulcer disease should be tested for H. pylori before discharge and receive 14-day bismuth quadruple therapy or standard triple therapy (depending on local clarithromycin resistance) if positive, combined with proton pump inhibitor therapy tailored to ulcer type and complications. 1

H. pylori Testing Strategy

Test every patient with a peptic ulcer for H. pylori infection before discharge. 2, 1 This is critical because eradication reduces rebleeding rates from 26% to 0-2%. 2, 3

Diagnostic Test Selection

• Urea breath test: sensitivity 88-95%, specificity 95-100% 2, 1
• Stool antigen test: sensitivity 94%, specificity 92% 2, 1
• Endoscopic biopsy (culture/histology) during upper endoscopy 2, 1

Critical pitfall: Repeat any negative H. pylori test obtained during acute bleeding episodes, as false-negative results are common in this setting. 1 Testing should ideally be performed 4-8 weeks after a bleeding episode for accuracy. 2

H. pylori Eradication Regimens

First-Line Therapy

When local clarithromycin resistance is <15-20%: 14-day standard triple therapy 2, 1

• PPI standard dose twice daily
• Clarithromycin 500 mg twice daily
• Amoxicillin 1000 mg twice daily (or metronidazole 500 mg twice daily if penicillin-allergic)

When clarithromycin resistance is high (>20%): 10-day sequential therapy 2, 1

• Days 1-5: PPI + amoxicillin 1000 mg twice daily
• Days 6-10: PPI + clarithromycin 500 mg + metronidazole 500 mg twice daily

Alternative first-line option: Bismuth quadruple therapy for 14 days 4 This is increasingly preferred given rising clarithromycin resistance globally.

Second-Line Therapy (After First-Line Failure)

10-day levofloxacin-based triple therapy 2, 1

• PPI standard dose twice daily
• Levofloxacin 500 mg once daily (or 250 mg twice daily)
• Amoxicillin 1000 mg twice daily

Timing in Bleeding Ulcers

Start eradication therapy after 72-96 hours of intravenous PPI administration, once oral feeding is reintroduced. 2 Delaying treatment until after discharge leads to reduced compliance and loss to follow-up. 2

Confirm eradication after completion of therapy using urea breath test or stool antigen test (not serology). 1, 5 If eradication is not documented, treat as treatment failure and retreat. 1

Proton Pump Inhibitor Management

Acute Bleeding Ulcers

For high-risk stigmata (active bleeding, visible vessel, adherent clot): Give IV PPI loading dose followed by continuous infusion for 72 hours after endoscopic hemostasis. 1 This is a strong recommendation based on moderate-quality evidence.

After 72-96 hours of IV PPI, switch to oral PPI twice daily for 14 days, then once-daily dosing thereafter. 2, 1

Duration Based on Ulcer Type

Uncomplicated duodenal ulcer: Prolonged PPI beyond H. pylori eradication is NOT required after successful eradication. 2

Gastric ulcer and complicated duodenal ulcer: Continue PPI until complete healing is confirmed and H. pylori eradication is documented. 2, 6 Gastric ulcers require longer acid suppression (8 weeks for ulcers >2 cm) and endoscopic follow-up to ensure healing. 2, 3

After ulcer healing: Discharge on once-daily PPI, with duration determined by underlying cause (ongoing NSAID use, antiplatelet therapy, failed eradication). 1

NSAID-Related Ulcer Management

Acute Management

Discontinue NSAIDs immediately if possible—this heals 95% of ulcers and reduces recurrence from 40% to 9%. 3

If NSAIDs cannot be discontinued: Treat with PPI therapy and test/treat for H. pylori. 6, 7 The combination of H. pylori infection and NSAID use synergistically increases bleeding risk more than sixfold. 8

Prevention When NSAIDs Must Be Resumed

For patients with prior ulcer history requiring NSAIDs: Prescribe a COX-2-selective inhibitor (celecoxib) PLUS a PPI. 1, 6 This combination is superior to either agent alone. 1

Do not use COX-2 inhibitor or PPI monotherapy in high-risk patients—combination therapy is mandatory. 1, 6

Eradicate H. pylori in NSAID users—this reduces peptic ulcer likelihood by 50%. 8, 9

Antiplatelet Therapy Management

Low-Dose Aspirin After Bleeding

In patients with established cardiovascular disease who develop ulcer bleeding, restart low-dose aspirin within 1-7 days (ideally 1-3 days) once bleeding is controlled. 1 The risk of cardiovascular mortality outweighs bleeding risk. 1

Add PPI therapy to all patients on single or dual antiplatelet regimens who have had prior ulcer bleeding. 1

H. pylori and Antiplatelet Therapy

Test and eradicate H. pylori before starting chronic antiplatelet therapy in patients with ulcer history. 2 H. pylori is an independent risk factor for ulcer bleeding in aspirin users (OR 4.7). 2

However, PPI therapy is more effective than H. pylori eradication alone in preventing recurrent bleeding in high-risk aspirin users. 2 In one study, 14.8% of patients had recurrent bleeding after eradication alone versus 1.6% with PPI therapy. 2

Anticoagulation Management

For patients requiring continued anticoagulation (warfarin or DOACs) after ulcer bleeding, use concomitant PPI therapy. 1 This is based on very low-quality evidence but represents the safest approach.

Follow-Up and Confirmation

Confirm H. pylori eradication 4-8 weeks after completing therapy using urea breath test or stool antigen test. 2, 1, 5 Do not use serology for confirmation. 5

Endoscopic follow-up is mandatory for gastric ulcers to ensure complete healing and exclude malignancy. 2, 6

Do not rely on a single negative test during acute bleeding—repeat testing is essential to avoid missed infection. 1

Key Clinical Pitfalls

• Empirical antimicrobial therapy without testing is NOT recommended in bleeding peptic ulcer. 2 Test first, then treat based on results.
• H₂-receptor antagonists should NOT be used for acute ulcer bleeding—they are inferior to PPIs. 1
• Somatostatin and octreotide are not routinely recommended for acute ulcer bleeding. 1
• Standard triple therapy should only be used when clarithromycin resistance is <15-20% in the community. 2, 4 Rising resistance rates make bismuth quadruple therapy increasingly preferred. 4, 9
• Patients 60 years and older with new dyspepsia require endoscopy to exclude malignancy, not just test-and-treat. 8, 5

Surgical Consultation

If endoscopic therapy fails, obtain surgical consultation immediately. 1 Percutaneous arterial embolization may be considered as an alternative when expertise is available. 1

Hospitalize patients for at least 72 hours after endoscopic hemostasis for high-risk stigmata. 1